Prudential PLC Has $34.98 Million Holdings in IDEXX Laboratories, Inc. $IDXX

Prudential PLC grew its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 11.9% in the 4th quarter, HoldingsChannel reports. The fund owned 51,709 shares of the company’s stock after purchasing an additional 5,507 shares during the quarter. Prudential PLC’s holdings in IDEXX Laboratories were worth $34,983,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently bought and sold shares of the stock. Westfield Capital Management Co. LP raised its position in shares of IDEXX Laboratories by 56.6% in the fourth quarter. Westfield Capital Management Co. LP now owns 147,447 shares of the company’s stock valued at $99,752,000 after buying an additional 53,318 shares in the last quarter. Vise Technologies Inc. raised its position in shares of IDEXX Laboratories by 27.5% in the fourth quarter. Vise Technologies Inc. now owns 1,197 shares of the company’s stock valued at $810,000 after buying an additional 258 shares in the last quarter. Cibc World Market Inc. raised its position in shares of IDEXX Laboratories by 208.2% in the fourth quarter. Cibc World Market Inc. now owns 23,857 shares of the company’s stock valued at $16,140,000 after buying an additional 16,115 shares in the last quarter. Marietta Investment Partners LLC raised its position in shares of IDEXX Laboratories by 185.2% in the fourth quarter. Marietta Investment Partners LLC now owns 1,383 shares of the company’s stock valued at $936,000 after buying an additional 898 shares in the last quarter. Finally, CIBC Asset Management Inc raised its position in shares of IDEXX Laboratories by 28.0% in the fourth quarter. CIBC Asset Management Inc now owns 37,818 shares of the company’s stock valued at $25,585,000 after buying an additional 8,274 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories Stock Performance

Shares of NASDAQ:IDXX opened at $564.74 on Friday. The company’s 50 day simple moving average is $563.32 and its 200 day simple moving average is $632.63. The stock has a market capitalization of $44.55 billion, a price-to-earnings ratio of 41.59, a price-to-earnings-growth ratio of 3.07 and a beta of 1.55. IDEXX Laboratories, Inc. has a 1 year low of $506.91 and a 1 year high of $769.98. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. The firm had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The company’s revenue was up 14.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, research analysts predict that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on IDXX shares. Wall Street Zen downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. UBS Group dropped their price target on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research report on Tuesday, April 28th. Piper Sandler dropped their price target on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research report on Monday, February 9th. Weiss Ratings downgraded shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Finally, Stifel Nicolaus decreased their price objective on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research note on Tuesday, March 31st. Seven equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $751.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.